Mild hypothermia in improving multiple organ dysfunction after cardiac arrest

BACKGROUND： Resuscitation after cardiac arrest （CA） with a whole-body ischemia–reperfusion injury causes brain injury and multiple organ dysfunction （MODS）. This study aimed to determine whether mild systemic hypothermia could decrease multiple organ dysfunctions after resuscitation from cardiac arrest.METHODS： The patients who had been resuscitated after cardiac arrest were reviewed. During the resuscitation they had been assigned to undergo therapeutic hypothermia （target temperature, 32°C to 34°C, measured in the rectum） over a period of 24 to 36 hours or to receive standard treatment with normothermia. Markers of different organ injury were evaluated for the ？ rst 72 hours after recovery of spontaneous circulation （ROSC）.RESULTS： At 72 hours after ROSC, 23 patients in the hypothermia group for whom data were available had favorable neurologic, myocardial, hepatic and pulmonic outcomes as compared with 26 patients in the normothermia group. The values of renal function were not signi？ cantly different between the two groups. However, blood coagulation function was badly injured in the hypothermia group.CONCLUSION： In the patients who have been successfully resuscitated after cardiac arrest, therapeutic mild hypothermia can alleviate dysfunction after resuscitation from cardiac arrest.

Late-onset multiple acyl-CoA dehydrogenase deficiency with cardiac syncope: A case report

BACKGROUND Multiple acyl-CoA dehydrogenase deficiency(MADD)is an uncommon autosomal recessive disorder of mitochondrial fatty acid beta-oxidation.Syncope is a transient loss of consciousness due to acute global cerebral hypoperfusion.Late-onset MADD with syncope has not been reported previously.CASE SUMMARY We report a 17-year-old girl with exercise intolerance and muscle weakness.She felt palpitation and shortness of breath after short bouts of exercise.She also suffered from a transient loss of consciousness many times.Muscle biopsy showed lipid storage.Genetic mutation analysis indicated a compound heterozygous mutation c.250G>A(p.A84T)and c.872T>G(p.V291G)in the ETFDH gene.The results of Holter electrocardiogram monitoring showed supraventricular tachycardia when the patient experienced a loss of consciousness.After treatment with riboflavin and carnitine,muscle weakness and palpitation symptoms improved rapidly.No loss of consciousness occurred,and the Holter electrocardiogram monitoring was normal.CONCLUSION Late-onset MADD with supraventricular tachycardia can cause cardiac syncope.Carnitine and riboflavin supplement were beneficial for treating the late-onset MADD with cardiac syncope.Attention should be paid to the prevention of cardiac syncope when diagnosing late-onset MADD.

Multiple left ventricular myxomas combined with severe rheumatic valvular lesions: A case report

BACKGROUND Primary cardiac tumors are uncommon,of which cardiac myxoma accounts for 50%-80%.Left ventricular myxoma has been rarely reported,accounting for only 3%-4%of all cardiac myxomas.Multiple left ventricular myxomas are,relatively,even rarer.CASE SUMMARY In this report,we present a case of multiple left ventricular myxomas combined with severe rheumatic valve lesions.Symptomatically,the patient presented with fatigue,shortness of breath,and palpitation after activities.The patient underwent complete surgical resection of multiple left ventricular myxomas combined with mechanical replacement of the mitral and aortic valves,tricuspid valvuloplasty.The patient recovered well after the operation,with no obvious related complications.CONCLUSION Multiple left ventricular myxomas may coexist with severe rheumatic valve disease.Operation is an effective treatment.

Thrombolysis and embolectomy in treatment of acute stroke as a bridge to open-heart resection of giant cardiac myxoma:A case report

BACKGROUND Cardiac embolism is a common cause of ischemic stroke in young adults.Neurological complications associated with atrial myxoma most frequently include cerebral infarct due to embolus.Early complete resection of giant cardiac myxoma is the key to its treatment and prevention of stroke recurrence.CASE SUMMARY A 42-year-old,previously healthy woman was admitted to the hospital with sudden-onset inability to speak and right-sided hemiplegia.While sweeping the floor 2 h prior to hospital admission,the patient developed sudden inability to express herself or understand what others were saying,accompanied by dyskinesia of the right limb,inability to walk or hold objects,and involuntary choreiform movements of the left upper limb.The patient was diagnosed with cerebral embolism and cardiac myxoma,complicated by left middle cerebral artery occlusion.The acute stroke was treated with intravenous thrombolytic therapy and arterial embolectomy as a bridging therapy to open resection of left atrial cardiac myxoma.The patient condition improved remarkably following initial thrombolysis and embolectomy and subsequently underwent emergency open resection of the atrial cardiac myxoma.She had no recurrence during 1-year follow-up.CONCLUSION Strong consideration should be given to urgent intravenous thrombolysis(rt-PA,alteplase)in young adult stroke patients at the time of hospital admission.The present case demonstrated a highly successful outcome that combined thrombolysis and arterial embolus retrieval as a bridge to early complete resection of a giant cardiac myxoma for both stroke treatment and recurrence prevention.

Familial cardiac myxoma with multifocal recurrences:a case report and review of the literature

We report a case of myxoma with multiple recurrences in both the atrium and ventricle in a 26-year-old woman five years after the surgical removal of left atrial myxoma, Her 52-year-old mother had a similar medical history. To our knowledge, this was the first familial case who suffered multifocal cardiac myxoma recurrences without any sign of the myxoma complex. Based on our understanding of the mechanism of recurrence, the approaches to prevent the recurrence, and markers to predict recurrence, we propose that multifocal recurrences, as reported herein, may result from a combination of familial predisposition and multifocal onset. The hi-atrial surgical approach and transesophageal echocardiography are preferred for patients with recurrent cardiac myxomas, especially for those with multiple recurrences and familial myxoma. Immunological and genetic screenings may help to identify family members at risk for developing this disease.

Clinical Signifi cance of Angiographically Detectable Neovascularity in Patients with Cardiac Myxoma

Background:Myxomas are the most common primary cardiac tumors.Angiographically detectable neovascularity(ADN)of myxoma is increasingly being reported as a result of the use of coronary angiography(CAG)to detect coronary artery disease.However,the clinical signifi cance of these fi ndings is not fully understood.Methods:We enrolled 59 patients with cardiac myxoma who also underwent CAG between January 2013 and October 2018.Patients were followed up for a mean of 28.9 months(range 1-69 months).The clinical features,echocardiography measurements,pathological examination fi ndings,CAG results,and outcomes during follow-up were compared between patients with ADN and patients without ADN.Results:ADN was found in 25 patients(42.4%).The arteries feeding the ADN included the right coronary artery(n=15),the left circumfl ex coronary artery(n=7),and both arteries(n=3).The patients with ADN had a higher proportion of eosinophils(3.2%vs.2.2%,P=0.03)and higher low-density lipoprotein cholesterol level(2.7 mmol/L vs.2.2 mmol/L,P=0.02).Myxoma pedicles were more likely to be located in the interatrial septum in patients with ADN(96%vs.73.5%,P=0.02).No signifi cant correlation was observed between the groups in clinical manifestations,atrial arrhythmia,myxoma size,cardiac chamber size,left ventricular ejection fraction,and the prevalence of complication with coronary artery disease[16%in the ADN group(n=4)vs.20.6%in the non-ADN group(n=7),P=0.66].However,patients with ADN tended to have a lower incidence of major adverse cardiac and cerebrovascular events on long-term follow-up(0%vs.14.7%,P=0.07).Conclusion:CAG-detected ADN in patients with cardiac myxoma is associated with a borderline lower rate of major adverse cardiac and cerebrovascular events.

Cardiac myxoma shedding leads to lower extremity arterial embolism:A case report

BACKGROUND Left cardiac myxoma(CM)is the most common benign tumor of primary cardiac tumors,but because of its special position caused by pathological physiology change,caused by the complications of the heavier,the surface is often accompanied by blood clots,once fall out,it causes peripheral vascular embolization,such as acute lower limb artery embo-lization,harmfulness is large,high morbidity,and easy to occur repeatedly.CASE SUMMARY A 67-year-old male patient suddenly appeared numbness and weakness of the left lower limb and could not walk without obvious incentive.The patient was finally diagnosed as left CM complicated with acute lower limb arterial embolism after completing cardiac ultrasound,computer tomography angiography,and histopathological analysis,such as hematoxylin-eosin stain staining,immunohistochemistry and special staining including alcian blue staining and periodic acid schiff staining.Arterial thrombosis was removed successfully by femoral artery thrombectomy,postoperative numbness and weakness of the patient’s left lower limb disappeared,skin temperature became warm,and dorsal foot artery pulsation was accessible.The patient was readmitted to the hospital 8 mo after discharge for left atrial mass resection,and was diagnosed as CM by postoperative histopathological examination.CONCLUSION Although CM is rare,it may be considered as the source of embolism in patients with acute limb ischemia.Repeated loss of thrombus on the tumor and its surface may lead to repeated embolism of peripheral vessels.Cardiac ultrasound is helpful for early diagnosis.Here,we use this case report to highlight left CM as an important cause of acute limb ischemia and to report our experience in the diagnosis and treatment of lower limb arterial embolism caused by CM detachment.

Cardiac Myxoma: 10 Years Study of Presentations, Resection and Outcome

Background: Cardiac myxoma is a very rare heart tumor which presents as life threatening mass in cardiac chamber. The tumor may present with vague symptoms which can lead to delay in diagnosis. Methods: 22 patients underwent complete excision of intracardiac myxoma between January 2011 and December 2020. Majority of the patients were females (60%) with mean age of 48.9 years who presented with symptoms of dyspnea on exertion. 3 patients had significant complications due to myxoma. 2 presenting with tumor embolism and limb ischemia while 1 patient presented with pulmonary edema. All patients were diagnosed by echocardiography which helped in evaluation of size and extent of tumor. Majority of patients underwent trans-septal biatrial approach for tumor excision. Results: 95% of patients survived the operation. The mean tumor size excised was 5.0 ± 1.6 cm in the largest diameter. 11 patients had sessile tumor while 1 patient had dumb bell tumor occupying both atria. 15 patients were surviving the operation while 2 deaths happened after 6 years of surgery. Conclusion: Cardiac myxomas are rare tumors which can cause severe systemic and cardiac symptoms in patients. Early diagnosis and immediate surgical management give excellent early and long-term results.

Cardiac myxomas:A narrative review

Cardiac myxomas are common primary neoplasms of the heart.They are biologically benign but“functionally malignant”because of the potential for embolization.They arise most commonly from the left atrium,but no chambers of the heart are immune.They may be sporadic in the majority but also familial as a part of the Carney complex.Two morphological forms exist:polypoid and papillary.Polypoid myxomas often present with obstructive features,while the papillary forms are more prone to embolization.Histogenesis is still controversial;the current view centres around origin from the primitive pluripotent mesenchymal cells.They may be of giant proportion,be calcified or get infected.Clinical presentation typically involves the triad of intracardiac obstruction,embolic events and constitutional symptoms.Precordial examination findings may simulate those of mitral or tricuspid stenosis.The presence of tumour plop and change of the physical findings with changing position may help differentiation between the two.Echocardiography is the investigation of choice.Echogenic polypoid or papillary mobile mass within the atrial cavity remaining attached to the interatrial septum through a stalk are the tell-tale echocardiographic features.Cardiac magnetic resonance and computed tomographic scanning may have incremental diagnostic value.Histopathological examination reveals abundant loose myxoid stroma with scattered round,polygonal or stellate cells with dense irregular nuclei.Genetic testing may detect mutations in the PRKAR1A gene in the familial form of cardiac myxoma,i.e.the Carney complex.Surgical excision is the mainstay of treatment with low operative mortality,excellent postoperative survival and low recurrence rate.The current trend favours minimal-access surgery with or without robotic assistance.Physicians should have appropriate preparedness to make a timely diagnosis and enthusiastic treatment to avoid potentially fatal complications.

Six Years Clinical Experience and Surgical Considerations in Management of Cardiac Myxoma in Iraqi Center for Heart Disease—Single Center Experience

Background: Cardiac myxomas are the most frequently encountered benign cardiac tumors that if left untreated are inexorably progressive and potentially fatal. Surgery is the only way of treatment, and if not treated with the right surgical technique recurrence occurs. Objectives: In this single center study we documented the patterns of presentation, localization, surgical approaches and outcome of cardiac myxomas. Methods: This is a retrospective study of 20 patients who underwent surgical removal of atrial myxoma from January 2010 to December 2015. All patients underwent general investigations, and echocardiography was performed on all patients and surgery was done using extracorporeal circulation and mild hypothermia. Results: The ages of the patients ranged from 14 years to 71 years, with a mean of 51.45 years. Most myxomas (75%) originated from left atrium, 20% from right atrium and biatrial in 5% of cases. The male-to-female ratio was 1:2.3 (14 females and 6 males). Myxomas were more common in blood group A+ and B+. Chief complaints were dyspnea (70%) and palpitation (50%). The majority of masses were attached to the interatrial septum (65%) and four of cases (20%) arose from the lateral wall. Right atrial trans-septal incision was used in 55% of cases. No recurrence was recorded in our study. Six patients had postoperative complications, mainly in the form of arrhythmia (3 cases), bleeding (0ne case) and renal failure (one case) which resulted in the death of the patient. Conclusions: Cardiac myxoma excision account for a very small percentage of cardiac procedures. Immediate surgical treatment is indicated because of high risk of embolization and sudden death. Cardiac myxomas can be excised with a low rate of mortality and morbidity. Follow-up examination, including echocardiography, should be performed regularly.

Revealing the crucial roles of suppressive immune microenvironment in cardiac myxoma progression

Cardiac myxoma is a commonly encountered tumor within the heart that has the potential to be life-threatening.However,the cellular composition of this condition is still not well understood.To fill this gap,we analyzed 75,641 cells from cardiac myxoma tissues based on single-cell sequencing.We defined a population of myxoma cells,which exhibited a resemblance to fibroblasts,yet they were distinguished by an increased expression of phosphodiesterases and genes associated with cell proliferation,differentiation,and adhesion.The clinical relevance of the cell populations indicated a higher proportion of myxoma cells and M2-like macrophage infiltration,along with their enhanced spatial interaction,were found to significantly contribute to the occurrence of embolism.The immune cells surrounding the myxoma exhibit inhibitory characteristics,with impaired function of T cells characterized by the expression of GZMK and TOX,along with a substantial infiltration of tumor-promoting macrophages expressed growth factors such as PDGFC.Furthermore,in vitro co-culture experiments showed that macrophages promoted the growth of myxoma cells significantly.In summary,this study presents a comprehensive single-cell atlas of cardiac myxoma,highlighting the heterogeneity of myxoma cells and their collaborative impact on immune cells.These findings shed light on the complex pathobiology of cardiac myxoma and present potential targets for intervention.

Primary Cardiac Tumors Operated on in Côte d’Ivoire: They Are Almost All Myxomas

Objective: Through this surgical series, we present the epidemiological and anatomical-clinical aspects and the surgical results concerning patients operated on for a primary cardiac tumor at the Abidjan Heart Institute. Materials and Method: This is a retrospective descriptive study covering the period of January 1982 to December 2022, based on the medical records of patients operated on for a primary cardiac tumor at the Abidjan Heart Institute. Results: Twenty-seven (27) patients underwent surgery for a primary cardiac tumor, including 14 women and 13 men with a mean age of 41.5 years (range 19 - 76 years). The main circumstances of discovery were exertional dyspnea, palpitation and syncope or pseudo-syncope. The main site was the septal wall of the left atrium. The diagnosis of myxoma was confirmed by pathological examination of the surgical specimen in 96.3% (n = 24) of the patients and it was a malignant large cell immunoblastic lymphoma of the myocardium in 3.7% (n = 1) of the patients. The mean largest diameter was 46.1 mm. The postoperative course was marked by an ischaemic stroke (n = 1);recurrence of a left atrial myxoma 5 years after the first tumor removal (n = 1). Two cases of death were noted, one due to the evolution of immunoblastic large cell lymphoma and the other due to an extracorporeal circulation accident. Conclusion: Almost all primary cardiac tumors operated on in Abidjan are myxomas. The circumstances of the discovery of these cardiac tumors are multiple and varied but dominated by exertional dyspnea, palpitation and syncope. Whatever their histological type, primary cardiac tumors are serious affections, in view of the haemodynamic and rhythmic disorders they cause.

Comparing Short-Term Outcomes of Right Mini-Thoracotomy and Median Sternotomy for Isolated Left Atrial Myxoma Excision

Background: Left atrial myxoma (LAM) is the most common heart tumor in adults, requiring prompt surgical removal to prevent complications like valvular obstruction or embolization. Objectives: This study aimed to compare early postoperative outcomes between two surgical approaches—right mini-thoracotomy and median sternotomy—for the removal of isolated left atrial myxoma. Methods: We conducted a prospective observational study at the Department of Cardiac Surgery, National Heart Foundation Hospital & Research Institute (NHFH&RI), Mirpur, Dhaka, from March 2017 to August 2019. Twenty-eight patients undergoing surgery for isolated left atrial myxoma were included. The surgical approach was determined by the operating surgeon. We analyzed outcomes like intubation time, Intensive Care Unit (ICU) stay, pain levels (Visual Analogue Scale score), and overall hospital stay using SPSS. Statistical significance was set at p Results: Patients in the right mini-thoracotomy group had longer mean intubation times (11.43 vs. 5.93 hours, p Conclusion: Despite longer intubation and ICU times, the right mini-thoracotomy approach offers a minimally invasive alternative for isolated left atrial myxoma excision, with favorable outcomes overall.

Risk factors for postoperative recurrence of cardiac myxoma and the clinical managements： a report of 5 cases in one center and review of literature

Background Recurrence or metastasis of myxomas is not rare risk factors for postoperative cardiac myxoma recurrence and to classification. and can lead to malignancy. We aimed to analyze the summarize its clinical characteristics, treatments and Methods The clinical data of 5 patients with recurrent cardiac myxoma were retrospectively analyzed and our clinical experience was summarized. Moreover, the relevant literatures were reviewed. Results All the five cases of primary myxomas were derived from atypical positions. One patient had early distant metastasis, one had family history, and two suffered malignant recurrence. The recurrence interval was （2.30＋2.16） years and the recurrent tumors were all found in different chambers from those of the corresponding primary tumors. Re-operation was performed after recurrence. One patient died of heart failure after malignant recurrence, and the other 4 cases had satisfactory therapeutic outcomes after re-operations. Our experience advocated a clinical classification of ＂typical＂ and ＂atypical＂ cardiac myxoma, the typical myxomas referred to the tumors locating at the left atria, with single pedicle, rooted at or around the fossa ovalis, involving no genetic causes, and the atypical myxomas included the familial tumors, tumors stemming from multiple chambers, rooted in abnormal positions of the left atrium, with evident genetic mutation, or with malignant tendency.

Cardiac arrhythmia with premature ventricular contractures induced by interferon beta in a patient with multiple sclerosis

Multiple sclerosis(MS)is an immune‑mediated inflammatory and neurodegenerative disease of the central nervous system.Interferon(IFN)beta is an active ingredient of five out of twelve disease modifying treatments approved for MS.We report a case of IFN‑beta‑induced cardiac arrhythmia with premature ventricular contractures in a patient recently diagnosed with MS.

Acute Myocardial Infarction: Mode of Revelation of a Left Atrium Myxoma

True, cardiac myxoma is a benign tumor. On the other hand, it is serious by its complications, in particular embolic. The diagnosis of acute coronary syndrome in connection with a myxoma of the left atrium is retained before the association of an emboligenic intracardiac myxoma and an acute coronary syndrome in the absence of atherosclerotic lesions and the absence of intracardiac thrombus. We report a case of left atrium myxoma complicated by acute coronary syndrome in a 50-year-old patient operated on in our department and we will review the literature.

心脏黏液瘤相关缺血性脑卒中临床特点和危险因素的单中心队列研究

目的 探讨心脏黏液瘤相关缺血性脑卒中的临床特点和危险因素,为心脏黏液瘤相关缺血性脑卒中的早期识别和诊断提供依据。方法 回顾性收集2010年1月至2020年12月就诊于首都医科大学附属北京安贞医院的心脏黏液瘤患者408例。分析心脏黏液瘤患者和心脏黏液瘤相关缺血性脑卒中患者的临床表现,并分析心脏黏液瘤相关缺血性脑卒中的危险因素。结果 全部408例心脏黏液瘤患者中,396例纳入分析,其中包括48例心脏黏液瘤相关缺血性脑卒中患者和348例心脏黏液瘤非脑卒中患者。心脏黏液瘤的临床症状不典型,以心脏梗阻、栓塞和全身系统症状为主。在心脏黏液瘤相关缺血性脑卒中急性期,患者神经功能缺损为轻中度,美国国立卫生研究院卒中量表评分为3(1,10)分,大部分患者(56.3%,27/48)以神经系统症状为首发和唯一表现。多因素Logistic回归分析结果显示,肿瘤宽度<30 mm、肿瘤高活动度、肿瘤表面血栓形成和B型脑钠肽(BNP)水平较低均为心脏黏液瘤相关缺血性脑卒中的独立危险因素(均P<0.05)。结论 心脏黏液瘤临床表现多样。心脏黏液瘤相关缺血性脑卒中患者急性期表现为有轻中度神经功能缺损。较窄的肿瘤宽度、肿瘤高活动度、肿瘤表面血栓形成和较低的BNP水平是心脏黏液瘤相关缺血性脑卒中发生的独立危险因素。

心脏黏液瘤合并缺血性卒中的手术方式和术后管理

目的探讨心脏黏液瘤合并缺血性卒中(cardiac myxoma combined with ischemic stroke,CM-IS)的手术方式、术后并发症及术后抗栓治疗,为心脏黏液瘤导致的心源性卒中的手术方式和术后管理提供依据。方法心脏黏液瘤分别采用传统胸骨正中开胸手术和经胸骨右侧第四肋间微创手术两种手术方式。回顾性收集了2010年1月1日至2020年12月31日于北京安贞医院住院治疗的全部心脏黏液瘤患者,并将患者分为心脏黏液瘤合并缺血性卒中组和非卒中组,对部分患者进行短期随访。分析心脏黏液瘤合并缺血性卒中的手术方式、术后并发症,术后抗栓治疗及短期预后。结果共有387例患者纳入分析,其中包括45例缺血性卒中患者和342例非卒中患者。缺血性卒中患者在胸骨正中切开术中,体外循环阻断时间(62.7 min±23.7 min vs.63.2 min±27.4 min,P=0.921)、住院天数(10.2±3.0 vs.10.0±3.5,P=0.596)和术后并发症(15.0%vs.9.5%,P=0.283),与非卒中患者均无显著差别,缺血性卒中患者同时行冠脉搭桥手术的比例更高(17.5%vs.5.6%,P=0.005),同时行心脏瓣膜手术的比例较低(2.5%vs.16.8%,P=0.018)。缺血性卒中患者在微创手术中,体外循环阻断时间(66.6 min±27.5 min vs.69.7 min±29.9 min,P=0.460)、住院天数(9.1±1.8 vs.11.2±4.3,P=0.268)和术后并发症(20.0%vs.13.2%,P=0.678),与非卒中患者亦无显著差别。缺血性卒中患者术后使用抗栓治疗的比例(37.8%vs.39.8%,P=0.471),与非卒中患者无显著差别;随访期间无脑卒中复发,死亡(4.3%vs.2.0%,P=0.481)和黏液瘤复发(2.2%vs.1.8%,P=0.825)的比例,两组亦无显著差别。缺血性卒中患者3年生存率为95.7%(95%CI:94.9~96.5)。结论心脏黏液瘤合并缺血性卒中患者在黏液瘤切除手术方法中,无论采取胸骨正中切除术,还是微创手术,都是安全、有效的,术后并发症少。卒中患者在黏液瘤切除术后无需常规给予抗栓治疗,预后良好,生存率高。

替格瑞洛在急性心肌梗死多支病变患者经皮冠状动脉介入治疗术后的效果

目的 探讨替格瑞洛在急性心肌梗死(AMI)多支病变患者经皮冠状动脉介入治疗(PCI)术后的效果。方法 选取2021年2月~2023年2月于河北省沧州中西医结合医院就诊的AMI多支病变患者156例,按照随机数字表法分为常规组78例、研究组78例。常规组PCI术前给予氯吡格雷,研究组PCI术前给予替格瑞洛。比较两组心功能指标[左心室舒张末期容积指数(LVEDVI)、左心室射血分数(LVEF)、左心室收缩末期容积指数(LVESVI)]、心肌微循环指标[右冠状动脉帧数(RCA CTFC)、左前降支帧数(LAD CTFC)、左回旋支帧数(LCX CTFC)]、心肌损伤指标[肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白I(CTn-I)]、血小板聚集率、Wnt/β-连环蛋白(Wnt/β-catenin)通路相关基因(Wnt mRNA、β-catenin mRNA)、炎症指标及术后6个月不良心血管事件(MACE)发生率。结果 研究组术后30 d的LVEDVI、LVESVI低于常规组[(55.34±5.24)ml/m^(2)比(65.79±6.32)ml/m^(2)、(32.63±2.74)ml/m^(2)比(36.22±3.38)ml/m^(2)]LVEF高于常规组[(57.32±4.25)%比(52.65±3.49)%],差异有统计学意义(P<0.05);术后7 d研究组RCA CTFC、LAD CTFC、LCX CTFC均低于常规组[(19.11±3.03)帧比(24.35±3.56)帧、(18.75±2.14)帧比(22.74±3.03)帧、(16.52±2.06)帧比(21.14±3.18)帧],差异有统计学意义(P<0.05);研究组术后24 h CK-MB、CTn-I水平均低于常规组[(32.16±4.17)U/L比(45.23±5.39)U/L、(5.13±1.08)ng/ml比(7.68±1.23)ng/ml],差异有统计学意义(P<0.05);研究组术后24 h、30 d血小板聚集率低于常规组(P<0.05);研究组术后30 d Wnt、β-catenin、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平低于常规组[(1.03±0.30)比(1.59±0.35)、(2.06±0.37)比(1.12±0.33)、(124.36±18.63)ng/ml比(164.79±24.78)ng/ml、(20.28±3.32)ng/ml比(37.26±4.27)ng/ml],差异有统计学意义(P<0.05);研究组术后6个月MACE发生率低于常规组(2.56%比11.54%,P<0.05)。结论 相较于氯吡格雷,AMI多支病变患者PCI术前给予替格瑞洛治疗的血小板抑制效果更为显著,可改善心功能、心肌微循环,减轻心肌损伤,抑制炎症反应,减少PCI术后MACE发生,其机制可能与抑制Wnt/β-catenin通路活化有关。

基于临床和超声特点的二元Logistic 回归模型预测心脏黏液瘤血管栓塞事件

目的基于临床和超声特点探究心脏黏液瘤(cardiac myxoma,CM)患者并发血管栓塞(vascular embolism,VE)的危险因素,并构建预测CM患者VE事件的二元Logistic回归模型。方法回顾性筛选2016年6月-2023年7月于山东大学齐鲁医院德州医院经病理证实为CM的患者120例,根据术前有无发生VE分为VE组和对照组,收集并对2组临床和超声心动图特点行单因素和多因素分析,建立Logistic回归模型,以采用受试者工作特征(ROC)曲线和Hosmer-Lemeshow检验评估模型的预测效能和拟合能力。结果单因素分析显示年龄、吸烟史、肿瘤形态和结构是CM患者VE发生的影响因素;多因素分析显示吸烟史、肿瘤形态不规则、肿瘤结构疏松是CM患者并发VE的独立危险因素。结论基于临床和超声特点建立的二元Logistic风险预测模型且具备较好的预测效能和拟合能力,可为心脏黏液瘤患者血管栓塞的预防提供一定的参考依据。